TearScience
TearScience is an American company founded in 2005 that develops, manufactures and markets ophthalmic medical devices aiding in the identification and treatment of Meibomian gland Dysfunction, also known as Dry eye disease,[1] which is a condition that affect as many as 25 million Americans. The company’s Lipiflow System was FDA cleared in June 2011 for treating meibomian gland dysfunction[2] and is currently installed in over 250 locations across the globe. The company is headquartered in Morrisville, North Carolina.
Products
LipiView Ocular Surface uses Interferometry to measure the thickness of the tear film oily lipid layer.[3] LipiFlow Thermal Pulsation System uses heat and pressure to unblock obstructed Meibomian glands[4] to reduce dry eye symptoms.[5]
References
- "Hawaiian Eye & Retina 2021 Meeting - Home". www.healio.com. Retrieved 2020-07-27.
- Lane SS, et al. (2012). "A new system, the LipiFlow, for the treatment of meibomian gland dysfunction". Cornea. 31 (4): 396–404. doi:10.1097/ico.0b013e318239aaea. PMID 22222996.
- Eom Y, Lee JS, Kang SY, Kim HM, Song JS (June 2013). "Correlation between quantitative measurements of tear film lipid layer thickness andmeibomian gland loss in patients with obstructive meibomian gland dysfunction and normal controls". American Journal of Ophthalmology. Epub 2013 Mar 7. 155 (6): 1104–1110. doi:10.1016/j.ajo.2013.01.008. PMID 23465270.
- Korb DR, Blackie CA (August 2010). "Restoration of meibomian gland functionality with novel thermodynamic treatment device-a case report". Cornea. 29 (8): 930–933. doi:10.1097/ICO.0b013e3181ca36d6. PMID 20531168.
- Greiner JV. (April 2012). "A single LipiFlow® Thermal Pulsation System treatment improves meibomian glandfunction and reduces dry eye symptoms for 9 months". Current Eye Research. 37 (4): 272–278. doi:10.3109/02713683.2011.631721. PMID 22324772.